Conjunctivitis Treatment Market Size & Share, by Drug Class (Antibiotics, Antiviral, Antiallergic, Artificial Tears); Disease Type (Bacterial, Chemical, Viral, Allergic Conjunctivitis); Route of Administration (Oral, Topical); End-user (Hospitals, Online Pharmacies, Retail Pharmacies & Drug Stores) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 4553
  • Published Date: Feb 24, 2023
  • Report Format: PDF, PPT

Companies Dominating the Conjunctivitis Treatment Landscape

top-features-companies
    • Novartis AG
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Aurobindo Pharma Limited
    • Cipla Limited
    • Viatris Inc.
    • Akorn Operating Company LLC
    • AbbVie Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Dr.Reddy’s Laboratories Limited
    • MICRO LABS LIMITED
    • Ocular Therapeutix, Inc. 

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Novartis AG acquired Kedalion Therapeutics and its AcuStream technology, a novel device to improve the Novartis ophthalmic portfolio.

  • AbbVie Inc. declared the U.S. Food and Drug Administration (FDA) approval of VUITY, a pilocarpine HCl ophthalmic solution of 1.25 % used for the treatment of presbyopia that affects 128 million Americans.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4553
  • Published Date: Feb 24, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing air pollution across the world, rising burden of bacterial conjunctivitis infection, and rising cases of neonatal conjunctivitis are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 4% over the forecast period, i.e., 2023-2033.

Associated Adverse Effects of Drugs, Stringent Government Regulations for Approval of New Drugs, and lack of visits to healthcare are estimated to be the growth hindering factors for the market expansion.

The market in the North America region is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are Novartis AG, Aurobindo Pharma Limited, Cipla Limited, Viatris Inc., Akorn Operating Company LLC, AbbVie Inc., Dr.Reddy’s Laboratories Limited, and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by drug class, disease type, route of administration, end-user, and by region.

The antiallergic segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying